Hiroaki Kakutani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hiroaki Kakutani has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Hiroaki Inoue
Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka 589-8511, Japan
1 shared publication - Hirokazu Tanaka
Department of Hematology, Faculty of Medicine, Kindai University, Osaka-Sayama 5898511, Osaka, Japan
1 shared publication - Itaru Matsumura
Department of Hematology and Rheumatology, Kindai University Faculty of Medicine , Osaka , Japan
1 shared publication - Jorge Luis Espinoza
Faculty of Health Sciences, Kanazawa University, Kanazawa, Japan
1 shared publication - Maiko Komori-Inoue
Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka 589-8511, Japan
1 shared publication - Shinya Rai
Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan
1 shared publication
Latest Publications
- Open Access
Epstein–Barr Virus-Induced Post-Transplant Lymphoproliferative Disorder of the Central Nervous System Successfully Treated with Chemo-Immunotherapy
Aplastic anemia is a rare blood disease characterized by the destruction of the hematopoietic stem cells (HSC) in the bone marrow that, in the majority of cases, is caused by an autoimmune reaction. Patients with aplastic anemia are treated with immunosuppressive drugs and some of them, especially younger individuals with a donor available, can be successfully treated with hematopoietic stem cell transplantation (HSCT). We report here a rare case of post-transplant lymphoproliferative disorder (PTLD) associated with Epstein–Barr virus (EBV) reactivation in a 30-year-old female patient who underwent allogeneic HSCT for severe aplastic anemia. The PTLD, which was diagnosed 230 days after transplantation, was localized exclusively in the central nervous system (specifically in the choroid plexus) and manifested with obvious signs of intracranial hypertension. After receiving three cycles of high dose methotrexate (HD-MTX) combined with rituximab, the patient achieved a complete clinical recovery with normalization of blood cell counts, no evidence of EBV reactivation, and no associated neurotoxicity.
Open AccessEpstein–Barr Virus-Induced Post-Transplant Lymphoproliferative Disorder of the Central Nervous System Successfully Treated with Chemo-Immunotherapy
Aplastic anemia is a rare blood disease characterized by the destruction of the hematopoietic stem cells (HSC) in the bone marrow that, in the majority of cases, is caused by an autoimmune reaction. Patients with aplastic anemia are treated with immunosuppressive drugs and some of them, especially younger individuals with a donor available, can be successfully treated with hematopoietic stem cell transplantation (HSCT). We report here a rare case of post-transplant lymphoproliferative disorder (PTLD) associated with Epstein–Barr virus (EBV) reactivation in a 30-year-old female patient who underwent allogeneic HSCT for severe aplastic anemia. The PTLD, which was diagnosed 230 days after transplantation, was localized exclusively in the central nervous system (specifically in the choroid plexus) and manifested with obvious signs of intracranial hypertension. After receiving three cycles of high dose methotrexate (HD-MTX) combined with rituximab, the patient achieved a complete clinical recovery with normalization of blood cell counts, no evidence of EBV reactivation, and no associated neurotoxicity.